Intestinal blood vessel-associated macrophages and gut-vascular barrier dysfunction in cirrhosis

HepatitisHepatology

Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease

J Hepatol

Fondevila MF, Kreimeyer H, Hsu CL, Tamargo-Azpilicueta J, Day LZ, Gritsenko M, Attah K, Cabré N, Harberts A, Tonetti FR, Yang Y, Yamazaki T, Schöler D, Eguileor A, Blasio C, Meijnikman AS, Zhang X, Garcia-Carbonell R, Hook V, Zhou E, Sun Z, Jacobs JM, Turner JR, Llorente C, AlcHepNet Investigators, Glass CK, Stärkel P, Reinheckel T, Diaz-Moreno I, Gonzalez DJ, Schnabl B

doi: 10.1016/j.jhep.2026.01.013

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

Hepatology

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Lancet Gastroenterol Hepatol

Lazarus JV, Agirre-Garrido L, White TM, Arora AK, Manolas MI, Diaz LA, Arab JP, Zelber-Sagi S, Alkhouri N, Spearman CW, Schattenberg JM, Kondili LA, Carrieri P, Lofton HF, Jaisinghani P, Kumar S, Duseja A, El-Kassas M, Takahasi H, Shawcross DL, Stine JG, Villota-Rivas M, Miralles-Sanchez JE, Pannain S, Brennan PN, MASLD/MASH Collaborators

doi: 10.1016/S2468-1253(25)00300-0

Hepatology

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Lancet Gastroenterol Hepatol

Loomba R, George J, Castera L, Francque S, Lawitz E, Shoeb A, Clausen JO, Andersen B, Larsen AB, Gluud LL

doi: 10.1016/S2468-1253(26)00123-8

Hepatology

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

J Gastroenterol Hepatol

Hsieh ML, Su TH, Lin YC, Chen YY, Tung CF, Huang LS, Wu CH, Peng YC, Hsieh VC

doi: 10.1111/jgh.70259

Further Publications

Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

BMC Gastroenterol

Hamood M, Al-Salehi MA, Hussein AF, Naji KM, Rawal R

doi: 10.1186/s12876-026-05160-2

Gastrointestinal CancerHepatology

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement

Gut

Wu CT, Targher G, Byrne CD, Younossi ZM, Armstrong MJ, Luu HN, Lesmana CRA, Rustgi VK, Thomas JA, Okabayashi K, Lee JWJ, El-Serag HB, Kim W, Zhang HJ, Lonardo A, Souza M, George ES, Yang W, Yilmaz Y, Papatheodoridis G, Sookoian S, Romero-Gómez M, Sebastiani G, Schattenberg JM, El-Kassas M, Chan WK, Ocama P, Lupșor-Platon M, Perera N, Alswat K, Méndez-Sánchez N, Wong VW, Chai J, Tilg H, Sung JJ, Zheng MH

doi: 10.1136/gutjnl-2025-337374

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

Inflammatory Bowel Disease

Integrated Assessment of Intestinal Barrier Function and Microscopic Inflammation Using Confocal Laser Endomicroscopy for Relapse Prediction in Ulcerative Colitis

United European Gastroenterol J

Minea H, Sfarti C, Chiriac S, Sîngeap AM, Danciu M, Blaj M, Cimpoesu CD, Iosep D, Muzică C, Balan G, Zenovia S, Avram R, Huiban L, Juncu S, Trifan A

doi: 10.1002/ueg2.70181

Related content

Macrophage-derived cathepsin B disrupts intestinal tight junctions through occludin degradation and promotes alcohol-associated liver disease

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial

Mediterranean Diet Adherence Is Associated With Reduced Liver Fibrosis Risk in Metabolic Dysfunction-Associated Steatotic Liver Disease

Association between the PNPLA3 I148M (rs738409) polymorphism and risk of metabolic dysfunction-associated steatotic liver disease: a meta-analysis (2015-2025)

Colorectal cancer in metabolic dysfunction-associated steatotic liver disease: an international Delphi consensus statement

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Integrated Assessment of Intestinal Barrier Function and Microscopic Inflammation Using Confocal Laser Endomicroscopy for Relapse Prediction in Ulcerative Colitis